WASHINGTON (dpa-AFX) - Palatin Technologies, Inc. (PTN) announced the U.S. FDA has notified the company that it may proceed with its clinical investigation of subcutaneous injection PL-8177 as a potential treatment for patients with ulcerative colitis. The notice to proceed was received following Palatin's submission of an investigational new drug application for the program.
Palatin expects to commence a Phase 1 single and multiple ascending dose study in the current quarter.
Copyright RTT News/dpa-AFX